|  %20%20%20%20%20%20 |
|
| Drilling Consolidation Drives Gains, Cancer Research Moves Ahead, and Accounting Woes Shake Tech |
|
| Consolidation in the offshore drilling industry brought major deal news, while progress in cancer research marked another step forward for clinical development. | Elsewhere, accounting-related concerns created fresh uncertainty for a technology company. |
|
| | Built to Last (Sponsored) | | | These 7 stocks are not quick trades for the next quarter but durable positions designed to compound for decades.
Each company has a fortress balance sheet, dependable cash flows, and a history of rewarding shareholders through thick and thin.
Several rank among the elite dividend payers investors watch closely year after year.
For investors who value resilience, consistency, and long-term wealth building,
this short list is hard to ignore.
Get instant access to all 7 stocks before this list moves behind the paywall.
(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy) |
|
| | Markets | U.S. stocks ticked higher as tech shares continued rebounding from last week's AI-driven selloff, lifting the broader market. | Gains were also helped by easing volatility and investors repositioning ahead of key jobs and inflation data later this week. | DJIA [+0.04%] S&P 500 [+0.47%]
|
| Nasdaq [+0.90%] Russell 2k [+0.74%]
|
|
|
|
| | Market-Moving News | Pharmaceuticals | Lilly Pays Billions to Skip the Lab | | Eli Lilly (NYSE: LLY) just agreed to acquire Orna Therapeutics for up to $2.4 billion in cash, gaining access to a platform that could fundamentally change how cell therapies are delivered. | Instead of extracting a patient's immune cells, Orna's technology aims to trigger that entire process inside the body using circular RNA and novel lipid nanoparticles. | The deal lands as Lilly continues pushing hard beyond obesity, stacking bets across oncology, immunology, and now next-generation cell therapy in rapid succession. | Skip the Lab, Treat the Patient | Current CAR-T therapies from Bristol Myers Squibb, Gilead, and Johnson & Johnson work, but the process is slow, expensive, and logistically heavy. | Orna wants to collapse that entire workflow into a single treatment step. | If the science holds, this is cell therapy that scales like a drug rather than a procedure. That changes the economics, and you start to see why Lilly paid full price for early-stage science. | Lilly Keeps Stacking the Deck | This acquisition follows a new partnership with China's Innovent Biologics, worth up to $8.85 billion in milestones across immunology and oncology. | The pattern is unmistakable. Lilly is not slowing down while the weight-loss franchise prints revenue. | It is spending aggressively to ensure the pipeline behind the blockbusters remains just as competitive, and you stop thinking of this as defense once the deal count keeps climbing. |
|
| | Government Contracts | NASA Just Handed Voyager the Keys to the Station | | Voyager Technologies (NYSE: VOYG) just locked in a new contract with NASA's Johnson Space Center worth up to $24.5 million over four years, covering mission management services for the International Space Station. | This is not a flashy lunar announcement or a rocket debut. It is the operational backbone that keeps payloads moving safely to and from orbit. | The deal covers payload integration, mission operations, safety compliance, and post-mission closeout. | Voyager has already completed over 50 task orders for NASA, and this contract makes that relationship structural through 2030. | Boring Work, Serious Moat | Space gets attention when rockets launch, but the real business sits in the repetitive, high-stakes execution that most companies cannot handle reliably. | Voyager is building your awareness of this company around one idea: make missions routine, safe, and repeatable. | Three new payload missions are expected to be onboarded next quarter, signaling that demand is not slowing. | A track record like this is how you go from contractor to infrastructure. | ISS Today, Starlab Tomorrow | The contract framework includes options for NASA to expand both scope and value over its lifetime. | That flexibility matters as the ISS transitions toward eventual decommission and commercial successors step in. | Voyager is already positioning to apply its mission execution playbook to | Starlab, the next-generation commercial platform. | If you control the operational layer during the transition era, the jump to commercial stations stops looking like a pivot and starts looking inevitable. |
|
| | Quietly Building (Sponsored) | | | The so-called "Magnificent Seven" have already been heavily bid up, leaving many investors searching for the next wave of potential market leaders.
A new group of seven stocks has been screened for robust cash flows, durable competitive advantages, and scalable global demand.
These companies sit outside the crowded mega-cap trade yet still target large, growing markets.
The full research report reveals each name and the detailed investment case behind them. | Click here to unlock instant, FREE access to "These 7 Stocks Will be Magnificent in 2026."
(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) |
|
| | Consumer Brands | $122 Million Says the Bunny Still Has Pull | | Playboy Inc (NASDAQ: PLBY) just sold 50% of its China, Hong Kong, and Macau operations to UTG Brands Management Group for $122 million in cash. | UTG takes over all day-to-day operations, and Playboy keeps a stake in the joint venture, with distributions still flowing back. | That is a clean structure for a brand that has spent years figuring out what it actually wants to be. | This is not a retreat from China. It is Playboy admitting that running operations overseas was never its strength and handing the keys to someone who does it better. | Cash Now, Royalties Later | The $122 million lands immediately, and the deal is expected to be accretive to earnings right away. | For a company trading under $3, that kind of cash injection changes the math on what comes next. | You also keep the upside. Playboy retains ownership of the joint venture, meaning annual distributions continue without the cost of managing a complex international operation. | The Brand Is the Business | Playboy has always been worth more as a licensing machine than as an operator. | This deal leans fully into that reality and lets UTG handle the execution in one of the most complicated consumer markets on the planet. | If your entire strategy is built around the power of a globally recognized name, this is exactly how you monetize it. Let someone else run the stores and collect the check. |
|
| | Want to make sure you never miss our post-market roundup? | Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone right after the closing bell rings.
Email's great. Texts are faster. | 👉 Click here to get our closing report to your cell for free! |
|
| | Top Winners and Losers | | | Valaris Limited [VAL] $83.82 (+34.29%) | Valaris surged after agreeing to be acquired by Transocean in a $5.8 billion all-stock transaction combining two major offshore drillers. | TransCode Therapeutics Inc [RNAZ] $10.72 (+20.31%) | TransCode climbed after submitting an FDA IND amendment for a Phase 2 trial of its RNA-based cancer therapy in colorectal cancer. | Gold.com, Inc [GOLD] $64.14 (+15.93%) | Gold.com rose after reporting quarterly earnings and revenue that far exceeded expectations, while a $150 million investment from Tether boosted confidence in its precious metals platform. |
| |
|
| | | | | | Kyndryl Holdings, Inc [KD] $10.59 (-54.94%) | Kyndryl plunged after disclosing an SEC-related review of its accounting and internal controls alongside executive departures and weaker guidance. | Pagaya Technologies Ltd [PGY] $14.19 (-23.87%) | Pagaya fell despite reporting strong earnings as investors reacted to softer-than-expected forward profitability guidance. | monday.com Ltd [MNDY] $77.63 (-20.79%) | Monday.com dropped after issuing weaker-than-expected revenue guidance, raising concerns about slowing growth in its customer base. |
| |
| | |
| | Poll: Pick the most "dangerous" friend to go shopping with: | | | | | | | That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback! | Thanks for reading. I'll see you at the next open! | Best Regards,
— Adam G.
Elite Trade Club |
|
| | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
0 التعليقات:
إرسال تعليق